Pharmacokinetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients [Estudio farmacocinetico y farmacodinamico de temsirolimus en pacientes con carcinoma de celulas renales].
Latest Information Update: 07 Apr 2012
Price :
$35 *
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacokinetics
- 29 Mar 2012 Planned end date changed from 20 Dec 2012 to 20 Dec 2013 as reported by European Clinical Trials Database.
- 27 Feb 2012 New trial record